Necrotising enterocolitis triggers a TNF-driven gut-blood-brain cascade that disrupts the blood-brain barrier and induces TNFR1-skewed neuronal apoptosis and pyroptosis.
Wang Lin-Yu LY, Chen Tzu-Hao TH, Wang Liang-Chao LC, Chien Lan-Hsiang LH et al.
Necrotising enterocolitis (NEC) in very-low-birthweight (VLBW) infants is associated with neurodevelopmental difficulties, but the mechanisms linking intestinal disease to brain injury remain unclear. We asked whether NEC propagates along a tumour necrosis factor alpha (TNF-α)-centred gut-blood-brain pathway that compromises the blood-brain barrier (BBB) and activates inflammatory neuronal death programmes. In a retrospective cohort, inflammatory biomarkers at symptom onset (C-reactive protein and procalcitonin) were related to Bayley-III composite scores at 24 months' corrected age. We then used a neonatal rat NEC model with daily oral etanercept, a soluble TNF receptor fusion protein, or saline from postnatal day 2 to day 14 to assess intestinal histopathology and permeability, circulating microbial products, inflammation, BBB permeability, early neurobehaviour, microglial activation, and neuronal apoptosis and pyroptosis with TNF receptor (TNFR) localisation. An intestinal-epithelial cell-primary cortical neuron transwell co-culture tested whether LPS-injured epithelium was sufficient to release TNF-α, disrupt barrier integrity, and injure neurons, and whether etanercept mitigated these effects. In infants, higher C-reactive protein and procalcitonin at NEC onset were associated with lower Bayley-III motor, cognitive, and language scores. In rats, NEC caused small-intestinal injury with tight-junction loss and permeability, elevated circulating microbial products and TNF-α, increased BBB leak, activated microglia, and induced neuronal apoptosis and pyroptosis with a TNFR1-skewed and TNFR2-reduced profile. NEC also impaired early sensorimotor performance, and worse performance was associated with higher circulating C-reactive protein, procalcitonin, and TNF-α. Etanercept reduced inflammatory burden, improved intestinal and BBB integrity, and improved sensorimotor performance. In co-culture, LPS activated epithelial NF-κB and MAPK signalling, increased epithelial TNF-α, and reduced barrier resistance. Neurons exposed to this inflammatory milieu showed TNFR1 upregulation, TNFR2 downregulation, activation of apoptotic effectors, and NLRP1 inflammasome-linked pyroptotic signalling, accompanied by synaptic injury. Etanercept blunted upstream epithelial signalling, preserved barrier function, and reduced TNFR1-skewed neuronal injury programmes. Acute inflammatory burden at presentation tracked with poorer 24-month neurodevelopment, and experimental data support TNF signalling as a plausible, modifiable relay linking barrier failure to BBB dysfunction, microglial activation, and TNFR1-skewed neuronal injury. These findings support risk stratification using routine biomarkers and motivate mechanism-informed trials targeting inflammatory amplification in NEC.